Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
- PMID: 12111443
- DOI: 10.1007/s007020200089
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
Abstract
Cholinesterase (ChE) inhibition represents the most efficacious treatment approach for Alzheimer's disease (AD) to date. This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in the cerebrospinal fluid (CSF) and cognitive change (measured by the Computerised Neuropsychological Test Battery [CNTB]) following administration of the ChE inhibitor, rivastigmine (Exelon). In 18 patients with mild to moderate AD, CNTB scores, activities of AChE and BuChE in the CSF, and plasma BuChE activity were determined prior to treatment with rivastigmine. Doses of rivastigmine were then titrated (1 mg b.i.d./week) to final doses of 1, 2, 3, 4, 5 or 6 mg b.i.d. (n = 3 per dose). Following treatment with the target dose of rivastigmine for at least 3 days, CNTB scores were re-determined. CSF samples were continuously collected together with plasma samples prior to and for 12 hours after the final dose of rivastigmine, and AChE and BuChE activities determined.AChE in CSF and BuChE in plasma were dose-dependently inhibited by rivastigmine treatment. The inhibition of BuChE in CSF was not clearly dose-dependent. A statistically significant correlation was observed between the change in CNTB summary score and inhibition of AChE activity (r = -0.56, p < 0.05) and BuChE activity (r = -0.65, p < 0.01) in CSF. Improvement in speed-, attention- and memory-related subtests of the CNTB correlated significantly with inhibition of BuChE but not AChE activity in CSF. Weak or absent correlation with change in cognitive performance was noted for inhibition of plasma BuChE. These results indicate that cognitive improvement with rivastigmine in AD is associated with central inhibition of ChEs and support a role for central BuChE in addition to AChE inhibition in modulating cholinergic function in AD.
Similar articles
-
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.Neurology. 2002 Aug 27;59(4):563-72. doi: 10.1212/wnl.59.4.563. Neurology. 2002. PMID: 12196650 Clinical Trial.
-
Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.J Clin Psychopharmacol. 1999 Dec;19(6):513-21. doi: 10.1097/00004714-199912000-00005. J Clin Psychopharmacol. 1999. PMID: 10587286
-
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.Curr Med Res Opin. 2005 Nov;21(11):1809-18. doi: 10.1185/030079905X65655. Curr Med Res Opin. 2005. PMID: 16307702 Clinical Trial.
-
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.Int J Clin Pract. 2002 Apr;56(3):206-14. Int J Clin Pract. 2002. PMID: 12018828 Review.
-
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.Eur Neurol. 2002;47(1):64-70. doi: 10.1159/000047952. Eur Neurol. 2002. PMID: 11803198 Review.
Cited by
-
Biological Activities and Chemical Composition of Methanolic Extracts of Selected Autochthonous Microalgae Strains from the Red Sea.Mar Drugs. 2015 Jun 3;13(6):3531-49. doi: 10.3390/md13063531. Mar Drugs. 2015. PMID: 26047482 Free PMC article.
-
Arginine administration decreases cerebral cortex acetylcholinesterase and serum butyrylcholinesterase probably by oxidative stress induction.Neurochem Res. 2004 Feb;29(2):385-9. doi: 10.1023/b:nere.0000013741.81436.e8. Neurochem Res. 2004. PMID: 15002734
-
A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Prim Care Companion CNS Disord. 2013;15(2):PCC.12r01412. doi: 10.4088/PCC.12r01412. Epub 2013 Mar 7. Prim Care Companion CNS Disord. 2013. PMID: 23930233 Free PMC article.
-
Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.Molecules. 2017 Jan 20;22(1):172. doi: 10.3390/molecules22010172. Molecules. 2017. PMID: 28117700 Free PMC article.
-
Behavioral and Biochemical Effects of an Arylhydrazone Derivative of 5-Methoxyindole-2-Carboxylic Acid in a Scopolamine-Induced Model of Alzheimer's Type Dementia in Rats.Molecules. 2024 Dec 3;29(23):5711. doi: 10.3390/molecules29235711. Molecules. 2024. PMID: 39683869 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical